Egle Therapeutics

Egle Therapeutics is a clinical-stage biotechnology company specializing in immunomodulation, developing novel approaches to modulate regulatory T cell (Treg) activity for cancer and autoimmune diseases. They have developed a proprietary translational platform to identify Treg targets and develop antibody-based candidate drugs. Their lead candidate, EGL-001, is in a Phase I/II clinical trial.

Funding Round:

Funding Amount: €9.3M

Date: 17-Mar-2025

Investors: Bpifrance

Markets: Biotech, Therapeutics, Oncology, Autoimmune Diseases

HQ: Paris, France

Founded: 2020

Website: https://www.egle-tx.com

LinkedIn: https://www.linkedin.com/company/egle-tx

Twitter:

Instagram:

Facebook:

Crunchbase: https://www.crunchbase.com/organization/egle-therapeutics

Pitchbook: https://pitchbook.com/profiles/company/439329-25


Similar Startups


Leave a Comment

    🔷 Buy VC Database 🟩 Buy Startup Database 🎁 Get Free Sample

    Share this: